WO1996028165A1 - Injection mensuelle utile comme contraceptif retard et comme hormonotherapie substitutive pour femmes dans la perimenopause et dans la premenopause - Google Patents
Injection mensuelle utile comme contraceptif retard et comme hormonotherapie substitutive pour femmes dans la perimenopause et dans la premenopause Download PDFInfo
- Publication number
- WO1996028165A1 WO1996028165A1 PCT/EP1996/001201 EP9601201W WO9628165A1 WO 1996028165 A1 WO1996028165 A1 WO 1996028165A1 EP 9601201 W EP9601201 W EP 9601201W WO 9628165 A1 WO9628165 A1 WO 9628165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- month
- estradiol
- replacement therapy
- injectable
- once
- Prior art date
Links
- 238000002657 hormone replacement therapy Methods 0.000 title claims abstract description 8
- 230000002254 contraceptive effect Effects 0.000 title abstract description 8
- 239000003433 contraceptive agent Substances 0.000 title abstract description 5
- 239000000583 progesterone congener Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 7
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 12
- 229960004766 estradiol valerate Drugs 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 8
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 8
- 229960001652 norethindrone acetate Drugs 0.000 claims description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 5
- 230000001076 estrogenic effect Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229960000978 cyproterone acetate Drugs 0.000 claims description 4
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 4
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 claims description 3
- 229960005416 estradiol cypionate Drugs 0.000 claims description 3
- 230000003152 gestagenic effect Effects 0.000 claims description 3
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960001359 estradiol 3-benzoate Drugs 0.000 claims description 2
- 150000002159 estradiols Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- -1 compounds norethisterone acetate Chemical class 0.000 claims 1
- 239000000262 estrogen Substances 0.000 abstract description 19
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract description 2
- 229960002568 ethinylestradiol Drugs 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 229940011871 estrogen Drugs 0.000 description 17
- 238000000034 method Methods 0.000 description 7
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 description 6
- 229960002082 norethindrone enanthate Drugs 0.000 description 6
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- NEDJKVIUOSOCNB-AWPSVMBFSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclo Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21.O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 NEDJKVIUOSOCNB-AWPSVMBFSA-N 0.000 description 3
- MVRUQONLTQUUHW-ASYYKIBUSA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 MVRUQONLTQUUHW-ASYYKIBUSA-N 0.000 description 3
- 229940127234 oral contraceptive Drugs 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960004474 levonorgestrel and estrogen Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Definitions
- the present invention relates to the use of a one-month injection (once-a-month injectable composition) containing an estrogenic and gestagenic component as active ingredients for the manufacture of a medicament for contraception and simultaneous hormone replacement therapy for peri- and premenopausal women.
- a monthly injection in the sense of the present invention means a hormone preparation which is injected once a month for women of childbearing age for contraception.
- This hormone preparation contains a gestagenic and an estrogenic component as active substances, each with a long enough effect to achieve a contraceptive effect for a period of one month.
- progestogen-only injectables are also available, which ensure long-term contraceptive protection, albeit with poor cycle control.
- US Pat. No. 4,826,831 already discloses a method for the hormonal treatment of menopausal, including perimenopausal and postmenopausal disorders (disorders), which relates in particular to treatment using a progestogen in conjunction with an estrogen.
- the estrogen can also be continuous or cyclical, i.e. H. with breaks.
- estrogens and progestogens are mentioned which are suitable for the purposes of this invention, including norethisterone acetate and medroxyprogesterone acetate as progestogens and estradiol valerate.
- norethisterone acetate and medroxyprogesterone acetate as progestogens and estradiol valerate.
- it should be possible to use all estrogens and progestogens that are also in oral contraceptives are conceivable. Adequate contraceptive protection is provided by the described
- Norethisterone acetate / estradiol valerate is also disclosed as a possible combination.
- progestogen and estrogen used are low: progestogen in a daily amount equivalent to 0.025 mg to 0.075 mg levonorgestrel and estrogen in a daily amount corresponding to 0.5 to 2.0 mg estradiol .
- the amount to be administered daily is the amount to be administered daily.
- estradiol valerate 20 mg to 100 mg estradiol valerate are given.
- Gestagen depot formulation for 3 months should be 50 to 500 mg medroxyprogesterone acetate or 20 to
- This patent also relates to pharmaceutical compositions for performing them
- Premenopause begins, onset of ailments, such as hot flushes, dryness of the
- US Pat. No. 4,826,831 expressly states that oral administration is not a method of contraception.
- peri- and premenopause should have their conventional meaning as described in "The Controversial Cli acteric", P.A. van Keep et al., Ed., MTP Press (1981) on page 9 can be understood.
- a one-month injection in the sense of the present invention should be understood to mean both the products already mentioned at the beginning and all other possible combinations of a natural estrogen with a progestogen.
- the two active components must be present in a depot formulation, the depot effect being achieved either through the special type of pharmaceutical formulation (for example microcrystalline suspension) or rather through the chemical structure of the progestogen and / or estrogen (for example through the esterification of free hydroxyl groups).
- the main estrogens here are 17 ⁇ -estradiol, estradiol-3-benzoate, estradiol-17-valerate, cypionate, undecylate, enanthate and or other estradiol esters (US Pat. No. 2,611,773, US Pat
- the gestagen component is preferably selected from the group of compounds
- Norethisterone acetate, norethisterone acetate, medroxyprogesterone acetate and cyproterone acetate Norethisterone acetate, norethisterone acetate, medroxyprogesterone acetate and cyproterone acetate.
- Tables LA and 2A list selected estrogens or gestagens to be used according to the present invention, with an indication of the preferred amount range.
- Tables 1B and 2B show the particularly preferred amounts of the respective estrogen or progestogen which are to be contained in a one-month syringe according to the present invention.
- the combination of medroxyprogesterone acetate and estradiol cypionate is preferred for producing a one-month syringe for peri- and premenopausal contraception; the combination of norethisterone enanthate / estradiol valerate is particularly preferred.
- the particularly preferred embodiment based on the progestogen / estrogen combination norethisterone enanthate / estradiol valerate not only offers a prophylactic effect with regard to osteoporosis, but in addition to the bone depletion-inhibiting effect of estrogen, a bone building effect caused by the norethis-terone enanthate is observed in this combination.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'utilisation d'une injection mensuelle qui contient des composants ÷strogènes et gestagènes comme principes actifs pour préparer un médicament contraceptif utile en même temps en hormonothérapie substitutive pour femmes dans la périménopause et dans la préménopause. On obtient avec ce médicament un effet contraceptif fiable avec un ÷strogène 'naturel' (sans éthinyl÷stradiol), ainsi qu'une thérapie efficace des premiers symptômes d'insuffisance d'÷strogène, ainsi qu'une prophylaxie de l'ostéoporose.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8527295A JPH11501649A (ja) | 1995-03-16 | 1996-03-15 | 閉経周辺期及び閉経前期にある女性に対する徐放性避妊薬としての及びホルモン補充療法に使用する１月用注射薬 |
| PL96322202A PL322202A1 (en) | 1995-03-16 | 1996-03-15 | Monthly injections as a contraceptive measure for and in substitute hormonal therapy of pre- and in-menopausal female patients |
| SK1239-97A SK123997A3 (en) | 1995-03-16 | 1996-03-15 | Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premenopausal women |
| NZ304027A NZ304027A (en) | 1995-03-16 | 1996-03-15 | Once a month injectable contraceptive comprising an estrogenic and gestagenic component for contraception and simultaneous hormone replacement therapy |
| CZ972896A CZ289697A3 (en) | 1995-03-16 | 1996-03-15 | Injection administered once a month as a depot contraception and for hormonal substitution therapy for women in perimenstrual and premenstrual pause |
| AU51108/96A AU713258B2 (en) | 1995-03-16 | 1996-03-15 | Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women |
| EP96907506A EP0814811A1 (fr) | 1995-03-16 | 1996-03-15 | Injection mensuelle utile comme contraceptif retard et comme hormonotherapie substitutive pour femmes dans la perimenopause et dans la premenopause |
| MX9707009A MX9707009A (es) | 1995-03-16 | 1996-03-15 | Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas. |
| NO974255A NO974255L (no) | 1995-03-16 | 1997-09-15 | Preparat for injeksjon én gang pr. måned og som er anvendbart som depot-befruktningshemmende middel og i hormon-erstatningsterapi for perimenopausale og premenopausale kvinner |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19510861A DE19510861A1 (de) | 1995-03-16 | 1995-03-16 | Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen |
| DE19510861.2 | 1995-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996028165A1 true WO1996028165A1 (fr) | 1996-09-19 |
Family
ID=7757668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/001201 WO1996028165A1 (fr) | 1995-03-16 | 1996-03-15 | Injection mensuelle utile comme contraceptif retard et comme hormonotherapie substitutive pour femmes dans la perimenopause et dans la premenopause |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0814811A1 (fr) |
| JP (1) | JPH11501649A (fr) |
| KR (1) | KR19980703058A (fr) |
| AR (1) | AR002283A1 (fr) |
| AU (1) | AU713258B2 (fr) |
| CA (1) | CA2215382A1 (fr) |
| CZ (1) | CZ289697A3 (fr) |
| DE (1) | DE19510861A1 (fr) |
| HU (1) | HUP9801691A3 (fr) |
| IL (1) | IL117516A (fr) |
| MX (1) | MX9707009A (fr) |
| NO (1) | NO974255L (fr) |
| NZ (1) | NZ304027A (fr) |
| PL (1) | PL322202A1 (fr) |
| SK (1) | SK123997A3 (fr) |
| WO (1) | WO1996028165A1 (fr) |
| ZA (1) | ZA962177B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0136011A2 (fr) * | 1983-08-05 | 1985-04-03 | Pre Jay Holdings Ltd. | Méthode de traitement hormonal de troubles de la périménopause, ménopause et postménopause et emballage à préparations multiples dans ce but |
-
1995
- 1995-03-16 DE DE19510861A patent/DE19510861A1/de not_active Withdrawn
-
1996
- 1996-03-15 WO PCT/EP1996/001201 patent/WO1996028165A1/fr not_active Application Discontinuation
- 1996-03-15 AR ARP960101766A patent/AR002283A1/es unknown
- 1996-03-15 KR KR1019970706467A patent/KR19980703058A/ko not_active Ceased
- 1996-03-15 PL PL96322202A patent/PL322202A1/xx unknown
- 1996-03-15 HU HU9801691A patent/HUP9801691A3/hu unknown
- 1996-03-15 CA CA002215382A patent/CA2215382A1/fr not_active Abandoned
- 1996-03-15 CZ CZ972896A patent/CZ289697A3/cs unknown
- 1996-03-15 AU AU51108/96A patent/AU713258B2/en not_active Ceased
- 1996-03-15 NZ NZ304027A patent/NZ304027A/xx not_active IP Right Cessation
- 1996-03-15 SK SK1239-97A patent/SK123997A3/sk unknown
- 1996-03-15 MX MX9707009A patent/MX9707009A/es not_active IP Right Cessation
- 1996-03-15 EP EP96907506A patent/EP0814811A1/fr not_active Withdrawn
- 1996-03-15 JP JP8527295A patent/JPH11501649A/ja not_active Ceased
- 1996-03-17 IL IL11751696A patent/IL117516A/xx not_active IP Right Cessation
- 1996-03-18 ZA ZA962177A patent/ZA962177B/xx unknown
-
1997
- 1997-09-15 NO NO974255A patent/NO974255L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0136011A2 (fr) * | 1983-08-05 | 1985-04-03 | Pre Jay Holdings Ltd. | Méthode de traitement hormonal de troubles de la périménopause, ménopause et postménopause et emballage à préparations multiples dans ce but |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19510861A1 (de) | 1996-09-19 |
| NO974255D0 (no) | 1997-09-15 |
| CA2215382A1 (fr) | 1996-09-19 |
| AR002283A1 (es) | 1998-03-11 |
| HUP9801691A3 (en) | 1999-03-01 |
| NO974255L (no) | 1997-11-14 |
| NZ304027A (en) | 2000-05-26 |
| MX9707009A (es) | 1997-11-29 |
| SK123997A3 (en) | 1998-02-04 |
| IL117516A0 (en) | 1996-07-23 |
| AU713258B2 (en) | 1999-11-25 |
| IL117516A (en) | 2000-07-26 |
| CZ289697A3 (en) | 1997-12-17 |
| PL322202A1 (en) | 1998-01-19 |
| AU5110896A (en) | 1996-10-02 |
| HUP9801691A2 (hu) | 1998-11-30 |
| ZA962177B (en) | 1996-07-29 |
| KR19980703058A (ko) | 1998-09-05 |
| JPH11501649A (ja) | 1999-02-09 |
| EP0814811A1 (fr) | 1998-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3916112C2 (fr) | ||
| DE69118494T2 (de) | Kontrazeptionsverfahren und Schema | |
| DE69804918T2 (de) | Sehr niedrigdosiertes orales Kontrazeptiv mit weniger Menstruationsblutungen und verzögerter Wirkung | |
| EP0148724B1 (fr) | Préparation multiphase séquentielle combinée et son application pour la contraception orale | |
| EP0499348B1 (fr) | Agent inhibiteur d'ovulation pour contraception hormonale | |
| EP0696454B1 (fr) | Préparation pharmaceutique pour la contraception/traitement hormonal de substitution avec des composés oestrogéniques biogéniques | |
| EP0628312B1 (fr) | Composition anticonceptionnel | |
| EP0770388B1 (fr) | Préparation contraceptive à plusieures phases, basée sur des oestrogènes naturels | |
| DE3855606T2 (de) | Verwendung von Melatonin zur Herstellung einer kontrazeptiven Zusammensetzung | |
| EP0835114B1 (fr) | Preparation pharmaceutique combinee, necessaire et methode de contraception orale | |
| DE69432752T2 (de) | Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält | |
| EP1310257A2 (fr) | Combinaison hormonale contraceptive | |
| DE69327319T2 (de) | Minimierung von mit progesteron verbundenen durchbruckblutungen | |
| DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
| DE4344462A1 (de) | Zusammensetzung für die Empfängnisverhütung | |
| DE19654609A1 (de) | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder | |
| DE4330234A1 (de) | Verwendung von Gestagenen und kompetitiven Progesteronantagonisten zur Herstellung von Arzneimitteln für die weibliche Fertilitätskontrolle sowie Mittel enthaltend ein Gestagen und einen kompetitiven Progesteronantagonisten | |
| WO1994002103A2 (fr) | Agent anti-ovulatoire de contraception hormonale | |
| EP0787002B1 (fr) | Antagonistes competitifs de la progesterone permettant de reguler a la demande la fecondite feminine | |
| WO1996032114A1 (fr) | Preparation pharmaceutique combinee de contraception hormonale | |
| DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
| DE3787386T2 (de) | In der Behandlung von Östrogeninsuffizienz zu verwendende Zusammensetzung. | |
| DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
| DD238921A5 (de) | Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung | |
| WO1996028165A1 (fr) | Injection mensuelle utile comme contraceptif retard et comme hormonotherapie substitutive pour femmes dans la perimenopause et dans la premenopause |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 96192615.5 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BY CA CN CZ HU JP KR MX NO NZ PL RU SK UA US VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1996907506 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 1996 527295 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 304027 Country of ref document: NZ Ref document number: 123997 Country of ref document: SK Ref document number: 1199700815 Country of ref document: VN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1019970706467 Country of ref document: KR |
|
| ENP | Entry into the national phase |
Ref document number: 2215382 Country of ref document: CA Ref document number: 2215382 Country of ref document: CA Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV1997-2896 Country of ref document: CZ |
|
| WWP | Wipo information: published in national office |
Ref document number: PV1997-2896 Country of ref document: CZ |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996907506 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 1998 913306 Country of ref document: US Date of ref document: 19980130 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 1019970706467 Country of ref document: KR |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV1997-2896 Country of ref document: CZ |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1019970706467 Country of ref document: KR |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996907506 Country of ref document: EP |